Post-hoc analyses comparing the efficacy of rasagiline 1mg/day ( n = 288 ) versus placebo ( n = 588 ) on key symptoms at 36 weeks , and on total-UPDRS scores over 72 weeks ( completer population : rasagiline 1mg/day n = 221 , placebo n = 392 ) were performed .